At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 778 enrolled
Drug / intervention
Baricitinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
In Brief
A Phase 3 clinical trial evaluating Baricitinib and Placebo for Systemic Lupus Erythematosus. Completed, enrolled 778 participants across 159 sites in 15 countries.
Detailed Summary
The reason for this study is to see how effective and safe the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSystemic Lupus Erythematosus
CountriesArgentina, Chile, Colombia, France, India, Italy, Japan, Philippines, Poland, Romania, Serbia, South Africa, South Korea, Spain, United States
CollaboratorsIncyte Corporation
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
Enrollment StartAug 2018
First PostedAug 2018
Primary CompletionSep 2021
Study CompletionOct 2021
TodayJul 2026
First PostedAug 6, 2018
Enrollment StartAug 2, 2018
Primary CompletionSep 24, 2021
Study CompletionOct 20, 2021
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 7.9 years ago
Interventions
Baricitinibdrug
Administered orally.
Placebodrug
Administered orally